0000315066-22-001801.txt : 20221026 0000315066-22-001801.hdr.sgml : 20221026 20221026122351 ACCESSION NUMBER: 0000315066-22-001801 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221024 FILED AS OF DATE: 20221026 DATE AS OF CHANGE: 20221026 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FMR LLC CENTRAL INDEX KEY: 0000315066 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41536 FILM NUMBER: 221332203 BUSINESS ADDRESS: STREET 1: 245 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6175706339 MAIL ADDRESS: STREET 1: 245 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02210 FORMER NAME: FORMER CONFORMED NAME: FMR CORP DATE OF NAME CHANGE: 19920717 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Prime Medicine, Inc. CENTRAL INDEX KEY: 0001894562 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 21 ERIE ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-465-0013 MAIL ADDRESS: STREET 1: 21 ERIE ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2022-10-24 1 0001894562 Prime Medicine, Inc. PRME 0000315066 FMR LLC 245 SUMMER STREET BOSTON MA 02210 0 0 0 1 See Remark 1 Common Stock 2022-10-24 4 C 0 4124375 A 4124375 I F-Prime Capital Partners Life Sciences Fund VI LP Common Stock 2022-10-24 4 C 0 98967 A 98967 I F-Prime Capital Partners Life Sciences Advisors Fund VI LP Common Stock 2022-10-24 4 C 0 11015 A 109982 I F-Prime Capital Partners Life Sciences Advisors Fund VI LP Common Stock 2022-10-24 4 C 0 3805080 A 3805080 I Entity managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned Common Stock 2022-10-24 4 C 0 423509 A 4228589 I Entity managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned Series A Convertible Preferred Stock 2022-10-24 4 C 0 4124375 D Common Stock 4124375 0 I F-Prime Capital Partners Life Sciences Fund VI LP Series A Convertible Preferred Stock 2022-10-24 4 C 0 98967 D Common Stock 98967 0 I F-Prime Capital Partners Life Sciences Advisors Fund VI LP Series B Convertible Preferred Stock 2022-10-24 4 C 0 11015 D Common Stock 11015 0 I F-Prime Capital Partners Life Sciences Advisors Fund VI LP Series A Convertible Preferred Stock 2022-10-24 4 C 0 3805080 D Common Stock 3805080 0 I Entity managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned Series B Convertible Preferred Stock 2022-10-24 4 C 0 423509 D Common Stock 423509 0 I Entity managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: F-Prime Capital Partners Life Sciences Advisors Fund VI LP (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VI LP. FPCPLSA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. Kevin M. Meagher, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson 2022-10-26